Training and Resources
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Eisai Prescribing information [External link]
LENVATINIB Eisai will be referred to as LENVATINIB across this page
KEYTRUDA® (pembrolizumab) plus LENVATINIB Eisai in advanced Renal Cell Carcinoma (aRCC)
KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of advanced renal cell carcinoma (aRCC) in adults.
HCP Resources
KEYTRUDA® (pembrolizumab) plus LENVATINIB CLEAR trial slide deck
For full information about KEYTRUDA and LENVATINIB adverse events, please refer to each product’s individual SmPC
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Your guide to recognising and managing KEYTRUDA® (pembrolizumab) plus LENVATINIB adverse events in aRCC
For full information about KEYTRUDA and LENVATINIB adverse events, please refer to each product’s individual SmPC
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Patient assets
To order printed versions of these diaries to your place of work, please contact msdukoncology@msd.com.
KEYTRUDA® (pembrolizumab) in combination with LENVATINIB patient booklet and diary
For full information about KEYTRUDA and LENVATINIB adverse events, please refer to each product’s individual SmPC
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing information [External link]
Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.
For more information about KEYTRUDA + LENVATINIB in aRCC:
Supporting documentation
KEYTRUDA Prescribing Information
LENVATINIB Prescribing information
By clicking the links above you will leave the MSD Connect website and be taken to an external website
